Companies: 10,795·Total market cap: $144.5T
Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.

CDTXNASDAQHealthcare
$221.38
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio—
52W High$221.42
52W Low$15.22
SEC Filings

Cidara Therapeutics, Inc. (CDTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001610618 · CDTX · NASDAQ · as of Jun 8, 2026

Filing snapshot

798
Total Filings
SCHEDULE 13G/A
Latest Form
2026-02-17
Most Recent
2015
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001610618 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-03-06
Fiscal Year End
Mar 6, 2025
Accession No.
0001610618-25-000017
Primary Document
cdtx-20241231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001610618 · Accession 0001610618-25-000017

Latest Key Filings

10-QQuarterly Report
CIDARA THERAPEUTICS, INC. FORM 10-Q
2025-11-06
View 10-Q on SEC
8-KCurrent Report
8-K
2026-01-07Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-01-30
View
15-12G15-12G
15-12G
2026-01-20
View
EFFECTEFFECT
EFFECT
2026-01-09
View
EFFECTEFFECT
EFFECT
2026-01-09
View
EFFECTEFFECT
EFFECT
2026-01-09
View
EFFECTEFFECT
EFFECT
2026-01-09
View
EFFECTEFFECT
EFFECT
2026-01-09
View
EFFECTEFFECT
EFFECT
2026-01-09
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-01-09
View
S-8 POSS-8 POS
S-8 POS
2026-01-07
View
S-8 POSS-8 POS
S-8 POS
2026-01-07
View
S-8 POSS-8 POS
S-8 POS
2026-01-07
View
Showing 1–15 of 519 filingsForm 4 / 144 hidden· 798 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001610618  |  Exchange: NASDAQ · Healthcare

Cidara Therapeutics, Inc. (NASDAQ: CDTX) has submitted 798 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2015. As a Healthcare sector company with CIK 0001610618, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Cidara Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Cidara Therapeutics, Inc. 10-K was filed on 2025-03-06 for fiscal year ending 2025. Historical CDTX 10-K annual reports are available from 2014 through 2025.

Investors researching Cidara Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
LEGN SEC Filings →SRRK SEC Filings →CPRX SEC Filings →BEAM SEC Filings →ADPT SEC Filings →IDYA SEC Filings →IRON SEC Filings →ZLAB SEC Filings →
→ CDTX Financials→ CDTX Earnings→ CDTX Insider Trades

Frequently Asked Questions

CDTX SEC Filings · 8 questions

Cidara Therapeutics, Inc. (CDTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 798 filings and access original documents at no cost. Cidara Therapeutics, Inc.'s CIK is 0001610618.

CDTX SEC filingsCidara Therapeutics, Inc. SEC documentsfind CDTX 10-K